ELI LILLY AND COMPANY Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment
ELI LILLY AND COMPANY (LLY) reported Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment of $28.00 million for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Income Statement › Other Income
us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments · last filed 2021-02-17
- ELI LILLY AND COMPANY defined benefit plan, net periodic benefit cost (credit), gain (loss) due to curtailment for the quarter ending 2018-09-30 was $28.00M.
| Period end | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 1 month | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 3 month | Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment 9 month |
|---|---|---|---|
| 2018-09-30 | $28.00M 10-Q · filed 2018-11-06 | $28.00M 10-Q · filed 2018-11-06 | |
| 2018-07-31 | $28.00M 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |